OncoSec Urges Shareholders Not to Fall for Alpha’s Disingenuous “Proposal” and Scheme to Prevent Fair Vote at Special Meeting

Jan 28, 2020 8:30am EST

Data from OncoSec’s Visceral Lesion Applicator (VLA) to be Presented at the Society of Interventional Oncology Annual Meeting

Jan 27, 2020 8:30am EST

OncoSec Announces the Appointment of Robert J. DelAversano, C.P.A, as Principal Accounting Officer and Controller

Jan 21, 2020 4:30pm EST

OncoSec Board Rejects Alpha Holdings “Proposal” and Announces New Special Meeting Date

Jan 16, 2020 8:30am EST

OncoSec Sends Letter to Shareholders Highlighting that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Have Recommended That OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction on the WHITE Proxy Card

Jan 06, 2020 8:30am EST

Institutional Shareholder Services Inc. ("ISS") Recommends OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction

Dec 26, 2019 8:30am EST

OncoSec Responds to Alpha’s “Proposal”

Dec 20, 2019 3:16pm EST

OncoSec Releases Presentation Spotlighting the Benefits of the Proposed CGP/Sirtex Transaction and Partnership

Dec 20, 2019 9:00am EST

OncoSec to Receive Approximately $885,000 Through New Jersey Technology Business Tax (NOL) Program

Dec 16, 2019 8:30am EST

OncoSec Presents Interim Data of 28.5% Objective Response Rate (ORR) from Ongoing KEYNOTE-890 Study Evaluating TAVO™ in Combination with KEYTRUDA® for Heavily Pretreated, Late-Stage, Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio Breast Cancer Symposium

Dec 13, 2019 8:30am EST